Background
==========

The neuroleptic malignant syndrome (NMS) is a rare but potentially fatal condition associated with antipsychotic medication. It is mainly characterized by fever, extrapyramidal symptoms, autonomic instability and an altered state of consciousness. It is primarily caused by dopamine (D~2~) receptors blockage in the nigrostriatal tract, mesocortical pathway and hypothalamic nuclei \[[@B1]\]. Recently, many authors have expressed the view that NMS is not caused by dopamine block alone. Other aminergic systems have also been implicated such as serotonin, norepinephrine, GABA e.t.c. \[[@B1],[@B2]\]. There are controversies as to whether atypical antipsychotics can cause \"classical\" forms of NMS \[[@B3]-[@B5]\].

During the last years, a condition of serotoninergic hyperstimulation called \"serotonin syndrome\" (SS) has been described. It is mainly associated with administration of antidepressive medication. The most frequent clinical features of this syndrome are changes in mental status, restlessness, myoclonus and hyperreflexia \[[@B6]\].

The difficulty of differentiating between NMS and SS has been well recognized \[[@B7],[@B8]\].

Olanzapine is an atypical antipsychotic, which exhibits greater affinity to serotonin (5-HT~2~) receptors than to dopamin (D~2~) receptors \[[@B9]\].

The aim of this study was to examine the recently reported NMS cases induced by olanzapine regarding SS clinical features and to elucidate phenomenological similarities between the two syndromes.

Methods
=======

A MEDLINE search related to olanzapine-induced NMS cases reported in the international literature from January 1996 to March 2001 was conducted. On the basis of the titles and information included in the abstracts, seventeen case reports were found \[[@B10]-[@B26]\]. Olanzapine-induced NMS cases have been presented and critically reviewed elswhere \[[@B27]\]. All cases were re-analyzed against SS clinical features according to Sternbach diagnostic criteria \[[@B6]\].

Results
=======

NMS associated with olanzapine has been reported in twelve males (mean age 44.5 ± 20.9 years) and in five females (mean age 54.2 ± 22.4 years). Schizophrenia was the primary diagnosis in nine of the patients (53%). The mean olanzapine dosage was 10.7 ± 4.3 mg/day.

As shown in table [1](#T1){ref-type="table"}, the SS clinical features presented in cases initially diagnosed as NMS were the following: fever (82%), mental status changes (82%), diaphoresis (47%), tremor (35%), agitation (23%), hyperreflexia (18%), incoordination (12%), myoclonus (6%), diarrhea (6%). There was no report on shivering.

###### 

Serotonin syndrome clinical features presented in NMS cases induced by olanzapine

  Case   Reference                      MS   A    MY   H    D    S   T    DI   I    F
  ------ ------------------------------ ---- ---- ---- ---- ---- --- ---- ---- ---- ----
  1      Johnson & Bruxner ^10^         \+                                     \+   \+
  2      Filice et al^11^               \+                  \+       \+             \+
  3      Moltz & Coeytaux^12^           \+   \+             \+                      \+
  4      Henel et al^13^                \+             \+   \+       \+             
  5      Burkhard et al ^14^            \+   \+                                \+   \+
  6      Emborg^15^                     \+                                          \+
  7      Apple & Van Hauer^16^          \+                  \+       \+             \+
  8      Hickey et al^17^                                   \+                      
  9      Margolese & Chouinard^18^                                                  \+
  10     Carcia Lopez et al^19^         \+                  \+            \+        \+
  11     Levenson^20^                   \+                  \+       \+             \+
  12     Gheorghiou et al^21^                          \+                           \+
  13     Haggarty et al^22^             \+   \+                                     
  14     Nyfort-Hansen & Alderman^23^   \+        \+   \+                           \+
  15     Jarventausta & Leinonen^24^    \+   \+                                     \+
  16     Stanfield & Privette^25^       \+                           \+             \+
  17     Sierra-Biddle et al^26^        \+                  \+       \+             \+

MS, Mental status changes; A, Agitation; MY, Myoclonus; H, Hyperreflexia; D, Diaphoresis; S, Shivering; T, Tremor; DI, Diarrhea; I, Incoordination; F, Fever

Three out of the ten SS clinical features set by Sternbach \[[@B6]\] were concurrently observed in eleven (65%) patients. Four clinical features were observed in seven (41%) patients and five clinical features in two (12%) patients.

Discussion
==========

According to Sternbach \[[@B6]\], for the establishment of the diagnosis of SS, the following three criteria should be fulfilled: a. presence of at least three of the ten proposed clinical features, b. addition to the therapeutic regiment or increase of a known serotonergic agent, and c. a neuroleptic had not been started or increased in dosage. If the last two criteria of drug use were excluded, the SS diagnosis in olanzapine-associated NMS cases could be made in eleven patients (65%). This means that there is a phenomenological overlap between NMS and SS symptoms in patients on olanzapine treatment. According to several authors NMS and SS can be differentiated with difficulty in many cases induced by antipsychotics or selective serotonin-receptor inhibitors (SSRI\'s) \[[@B7],[@B8]\].

The atypical or moderate forms of NMS attributed to novel antipsychotics (that have greater affinity to serotonin 5-HT~2A~receptors than to dopamine D~2~receptors) and the overlapping in clinical features between SS and NMS observed in patients treated with olanzapine, reinforce the view that the two syndromes may share the same underlying pathophysiology, i.e. imbalance between aminergic systems, despite differences in the causative drugs \[[@B28]\].

According to Fink \[[@B29]\], NMS and SS are non-specific generalized neurotoxic syndromes. This author recommends the immediate withdrawal of the offending agent and the administration of benzodiazepines in the early stages in both these syndromes.

Further studies, particularly of prospective nature are warranted in patients receiving conventional or atypical antipsychotics as well as serotoninergic agents in order to elucidate the common elements between NMS and SS regarding phenomenology, pathophysiology and treatment response.

Study limits
============

This is a retrospective analysis of the reported NMS cases induced by olanzapine. The fact that the data were collected from published case reports by other authors, has an inherent bias. The major limitation of this study stems from the lack of detailed information provided regarding the SS clinical symptoms, since the authors were mainly focusing on the description of NMS symptomatology.
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